Press Releases and Statements

CHPA Submits Comments on FDA Proposed Rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use

(NEW YORK) – The Consumer Healthcare Products Association (CHPA) Educational Foundation held its 7th Annual Gala last night at the Plaza Hotel in New York City.

The Consumer Healthcare Products Association (CHPA) Educational Foundation today announced an educational pilot launch to help consumers choose over-the-counter (OTC) pain relievers at the point of purchase

“As flu season begins, CHPA remains in close contact with our member companies who are currently meeting the elevated demand for safe and effective children’s pain reliever products.

Consumer Healthcare Products Association (CHPA) responds to findings from the “Supplements, Placebo, or Rosuvastatin (SPORT)” Study published in the Journal of the American College of Cardiology.

Jay Sirois, PhD, CHPA’s vice president of regulatory & scientific affairs, and co-author of the paper, Considerations for determining safety of probiotics: A USP perspective

The Consumer Healthcare Products Association (CHPA) applauds the U.S. Food and Drug Administration’s (FDA) final rule establishing a regulatory category for over-the-counter (OTC) hearing aids which will officially take effect Monday.

(WASHINGTON, DC) – Consumer Healthcare Products Association (CHPA) President and CEO, Scott Melville, today released the below statement following congressional passage of a short-term spending package to fund the Federal Government through Dec. 16. Included in this Continuing Resolution is legislation to reauthorize the U.S. Food and Drug Administration’s (FDA) user fee programs for prescription drugs, generic drugs, biosimilars, and medical devices over the next five years.

(Bethesda, MD) – The Consumer Healthcare Products Association (CHPA) today announced its first-ever Regulatory & Scientific Affairs Career Achievement Award winners at its annual Regulatory, Scientific & Quality (RSQ) conference in Bethesda.

CHPA Senior Vice President of Dietary Supplements Duffy MacKay today released the following statement in response to results from a recent COSMOS-Mind study, revealing statistically significant improvement on global cognition in participants who took a multivitamin over the course of the long-term clinical trial:

CHPA President and CEO, Scott Melville, today released the following statement in response to the U.S. Food and Drug Administration’s announcement of a joint meeting between its Advisory Committees on Nonprescription Drugs and Obstetrics and Reproductive and Urologic Drugs.